Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: han g. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Lebwohl MG, Stein Gold L, Papp K, Han G, Pariser DM, Lin T, Harris S, Jacobson A. Lebwohl MG, et al. Among authors: han g. J Eur Acad Dermatol Venereol. 2021 May;35(5):1152-1160. doi: 10.1111/jdv.17113. Epub 2021 Feb 7. J Eur Acad Dermatol Venereol. 2021. PMID: 33428282 Clinical Trial.
Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry.
Jin JQ, Cronin A, Roberts-Toler C, Yeroushalmi S, Hadeler E, Spencer RK, Elhage KG, Gondo G, Wallace EB, Reddy SM, Han G, Kaffenberger J, Davis MS, Hakimi M, Scher JU, Armstrong AW, Bhutani T, McLean RR, Liao W. Jin JQ, et al. Among authors: han g. J Am Acad Dermatol. 2023 Nov;89(5):974-983. doi: 10.1016/j.jaad.2023.06.058. Epub 2023 Jul 24. J Am Acad Dermatol. 2023. PMID: 37495173 Free article.
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.
Chat VS, Ellebrecht CT, Kingston P, Gondo G, Bell S, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong AW. Chat VS, et al. Among authors: han g. J Am Acad Dermatol. 2024 Feb 7:S0190-9622(24)00243-3. doi: 10.1016/j.jaad.2023.12.070. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38331098
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Egeberg A, et al. Among authors: han g. Dermatol Ther (Heidelb). 2024 Apr;14(4):1007-1018. doi: 10.1007/s13555-024-01147-7. Epub 2024 Apr 22. Dermatol Ther (Heidelb). 2024. PMID: 38647975 Free PMC article.
5,463 results